These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
315 related articles for article (PubMed ID: 31806595)
1. Dynamic Contrast-Enhanced MR Imaging of Nonenhancing T2 High-Signal-Intensity Lesions in Baseline and Posttreatment Glioblastoma: Temporal Change and Prognostic Value. Hwang I; Choi SH; Park CK; Kim TM; Park SH; Won JK; Kim IH; Lee ST; Yoo RE; Kang KM; Yun TJ; Kim JH; Sohn CH AJNR Am J Neuroradiol; 2020 Jan; 41(1):49-56. PubMed ID: 31806595 [TBL] [Abstract][Full Text] [Related]
2. Prognostic Value of Dynamic Contrast-Enhanced MRI-Derived Pharmacokinetic Variables in Glioblastoma Patients: Analysis of Contrast-Enhancing Lesions and Non-Enhancing T2 High-Signal Intensity Lesions. Kang Y; Hong EK; Rhim JH; Yoo RE; Kang KM; Yun TJ; Kim JH; Sohn CH; Park SW; Choi SH Korean J Radiol; 2020 Jun; 21(6):707-716. PubMed ID: 32410409 [TBL] [Abstract][Full Text] [Related]
3. Cluster Analysis of DSC MRI, Dynamic Contrast-Enhanced MRI, and DWI Parameters Associated with Prognosis in Patients with Glioblastoma after Removal of the Contrast-Enhancing Component: A Preliminary Study. Chung H; Seo H; Choi SH; Park CK; Kim TM; Park SH; Won JK; Lee JH; Lee ST; Lee JY; Hwang I; Kang KM; Yun TJ AJNR Am J Neuroradiol; 2022 Nov; 43(11):1559-1566. PubMed ID: 36175084 [TBL] [Abstract][Full Text] [Related]
4. Comparison between the Prebolus T1 Measurement and the Fixed T1 Value in Dynamic Contrast-Enhanced MR Imaging for the Differentiation of True Progression from Pseudoprogression in Glioblastoma Treated with Concurrent Radiation Therapy and Temozolomide Chemotherapy. Nam JG; Kang KM; Choi SH; Lim WH; Yoo RE; Kim JH; Yun TJ; Sohn CH AJNR Am J Neuroradiol; 2017 Dec; 38(12):2243-2250. PubMed ID: 29074633 [TBL] [Abstract][Full Text] [Related]
5. Prognostic Predictions for Patients with Glioblastoma after Standard Treatment: Application of Contrast Leakage Information from DSC-MRI within Nonenhancing FLAIR High-Signal-Intensity Lesions. Kim SH; Cho KH; Choi SH; Kim TM; Park CK; Park SH; Won JK; Kim IH; Lee ST AJNR Am J Neuroradiol; 2019 Dec; 40(12):2052-2058. PubMed ID: 31727756 [TBL] [Abstract][Full Text] [Related]
6. The Added Prognostic Value of Preoperative Dynamic Contrast-Enhanced MRI Histogram Analysis in Patients with Glioblastoma: Analysis of Overall and Progression-Free Survival. Choi YS; Kim DW; Lee SK; Chang JH; Kang SG; Kim EH; Kim SH; Rim TH; Ahn SS AJNR Am J Neuroradiol; 2015 Dec; 36(12):2235-41. PubMed ID: 26338911 [TBL] [Abstract][Full Text] [Related]
7. Multiparametric MR Imaging of Diffusion and Perfusion in Contrast-enhancing and Nonenhancing Components in Patients with Glioblastoma. Boonzaier NR; Larkin TJ; Matys T; van der Hoorn A; Yan JL; Price SJ Radiology; 2017 Jul; 284(1):180-190. PubMed ID: 28240563 [TBL] [Abstract][Full Text] [Related]
8. Prognosis prediction of non-enhancing T2 high signal intensity lesions in glioblastoma patients after standard treatment: application of dynamic contrast-enhanced MR imaging. Kim R; Choi SH; Yun TJ; Lee ST; Park CK; Kim TM; Kim JH; Park SW; Sohn CH; Park SH; Kim IH Eur Radiol; 2017 Mar; 27(3):1176-1185. PubMed ID: 27357131 [TBL] [Abstract][Full Text] [Related]
9. Glioblastoma treated with concurrent radiation therapy and temozolomide chemotherapy: differentiation of true progression from pseudoprogression with quantitative dynamic contrast-enhanced MR imaging. Yun TJ; Park CK; Kim TM; Lee SH; Kim JH; Sohn CH; Park SH; Kim IH; Choi SH Radiology; 2015 Mar; 274(3):830-40. PubMed ID: 25333475 [TBL] [Abstract][Full Text] [Related]
10. Assessment of Progression-Free-Survival in Glioblastomas by Intratreatment Dynamic Contrast-Enhanced MRI. Bisdas S; Smrdel U; Bajrovic FF; Surlan-Popovic K Clin Neuroradiol; 2016 Mar; 26(1):39-45. PubMed ID: 25164691 [TBL] [Abstract][Full Text] [Related]
11. Prognostic Prediction Based on Dynamic Contrast-Enhanced MRI and Dynamic Susceptibility Contrast-Enhanced MRI Parameters from Non-Enhancing, T2-High-Signal-Intensity Lesions in Patients with Glioblastoma. Jo SW; Choi SH; Lee EJ; Yoo RE; Kang KM; Yun TJ; Kim JH; Sohn CH Korean J Radiol; 2021 Aug; 22(8):1369-1378. PubMed ID: 33987994 [TBL] [Abstract][Full Text] [Related]
12. Clinical parameters outweigh diffusion- and perfusion-derived MRI parameters in predicting survival in newly diagnosed glioblastoma. Burth S; Kickingereder P; Eidel O; Tichy D; Bonekamp D; Weberling L; Wick A; Löw S; Hertenstein A; Nowosielski M; Schlemmer HP; Wick W; Bendszus M; Radbruch A Neuro Oncol; 2016 Dec; 18(12):1673-1679. PubMed ID: 27298312 [TBL] [Abstract][Full Text] [Related]
13. Nonenhancing peritumoral hyperintense lesion on diffusion-weighted imaging in glioblastoma: a novel diagnostic and specific prognostic indicator. Kolakshyapati M; Adhikari RB; Karlowee V; Takayasu T; Nosaka R; Amatya VJ; Takeshima Y; Akiyama Y; Sugiyama K; Kurisu K; Yamasaki F J Neurosurg; 2018 Mar; 128(3):667-678. PubMed ID: 28362236 [TBL] [Abstract][Full Text] [Related]
14. Dynamic contrast-enhanced MR imaging in predicting progression of enhancing lesions persisting after standard treatment in glioblastoma patients: a prospective study. Yoo RE; Choi SH; Kim TM; Park CK; Park SH; Won JK; Kim IH; Lee ST; Choi HJ; You SH; Kang KM; Yun TJ; Kim JH; Sohn CH Eur Radiol; 2017 Aug; 27(8):3156-3166. PubMed ID: 27975145 [TBL] [Abstract][Full Text] [Related]
15. Determining a cut-off residual tumor volume threshold for patients with newly diagnosed glioblastoma treated with temozolomide chemoradiotherapy: A multicenter cohort study. Woo PYM; Ho JMK; Tse TPK; Lam SW; Mak CHK; Chan DTM; Lee MWY; Wong ST; Chan KY; Poon WS J Clin Neurosci; 2019 May; 63():134-141. PubMed ID: 30712777 [TBL] [Abstract][Full Text] [Related]
16. Response Assessment in Neuro-Oncology criteria, contrast enhancement and perfusion MRI for assessing progression in glioblastoma. Tensaouti F; Khalifa J; Lusque A; Plas B; Lotterie JA; Berry I; Laprie A; Cohen-Jonathan Moyal E; Lubrano V Neuroradiology; 2017 Oct; 59(10):1013-1020. PubMed ID: 28842741 [TBL] [Abstract][Full Text] [Related]
17. Discrimination between Glioblastoma and Solitary Brain Metastasis: Comparison of Inflow-Based Vascular-Space-Occupancy and Dynamic Susceptibility Contrast MR Imaging. Li X; Wang D; Liao S; Guo L; Xiao X; Liu X; Xu Y; Hua J; Pillai JJ; Wu Y AJNR Am J Neuroradiol; 2020 Apr; 41(4):583-590. PubMed ID: 32139428 [TBL] [Abstract][Full Text] [Related]
18. Intratumoral Heterogeneity of Glioblastoma Infiltration Revealed by Joint Histogram Analysis of Diffusion Tensor Imaging. Li C; Wang S; Yan JL; Piper RJ; Liu H; Torheim T; Kim H; Zou J; Boonzaier NR; Sinha R; Matys T; Markowetz F; Price SJ Neurosurgery; 2019 Oct; 85(4):524-534. PubMed ID: 30239840 [TBL] [Abstract][Full Text] [Related]
19. Mitotic Activity in Glioblastoma Correlates with Estimated Extravascular Extracellular Space Derived from Dynamic Contrast-Enhanced MR Imaging. Mills SJ; du Plessis D; Pal P; Thompson G; Buonacorrsi G; Soh C; Parker GJ; Jackson A AJNR Am J Neuroradiol; 2016 May; 37(5):811-7. PubMed ID: 26705318 [TBL] [Abstract][Full Text] [Related]
20. Outcome prediction in patients with glioblastoma by using imaging, clinical, and genomic biomarkers: focus on the nonenhancing component of the tumor. Jain R; Poisson LM; Gutman D; Scarpace L; Hwang SN; Holder CA; Wintermark M; Rao A; Colen RR; Kirby J; Freymann J; Jaffe CC; Mikkelsen T; Flanders A Radiology; 2014 Aug; 272(2):484-93. PubMed ID: 24646147 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]